**Name of Journal:** *World Journal of Clinical Infectious Diseases*

**Manuscript NO:** 71285

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Mutations of the *brpR* and *brpS* genes affect biofilm formation in *Staphylococcus aureus***

ZankA *et al. S. aureus* biofilm regulation

Allison Zank, Lillian Schulte, Xavier Brandon, Lauren Carstensen, Amy Wescott, William R Schwan

**Allison Zank, Lillian Schulte, Xavier Brandon, Lauren Carstensen, Amy Wescott, William R Schwan,** Department of Microbiology, University of Wisconsin-La Crosse, La Crosse, WI 54601, United States

**Author contributions:** Zank A, Wescott A, and Schwan WR designed the research study; Zank A, Schulte L, Brandon X, Carstensen L, Wescott A, and Schwan WR performed the research; Zank A, Brandon X, and Schwan WR contributed new plasmids; Zank A, and Schwan WR analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.

**Supported by** National Science Foundation Graduate Research Program to Zank A, No. 0002016179620.

**Corresponding author: William R Schwan, PhD, Professor,** Department of Microbiology, University of Wisconsin-La Crosse, 1725 State St, La Crosse, WI 54601, United States. wschwan@uwlax.edu

**Received:** September 2, 2021

**Revised:** December 3, 2021

**Accepted: February 12, 2022**

**Published online:**

**Abstract**

BACKGROUND

In the United States, *Staphylococcus aureus* (*S. aureus*) kills tens of thousands of individuals each year and the formation of a biofilm contributes to lethality. Biofilm-associated infections are hard to treat once the biofilm has formed. A new stilbene drug, labeled SK-03-92, was shown to kill *S. aureus* and affected transcription of two genes tied to a putative two-component system (TCS) we have named *brpR* (biofilm regulating protein regulator) and *brpS* (biofilm regulating protein sensor).

AIM

To determine if BrpR and BrpS regulate biofilm formation, *brpR* and *brpS* mutants were assessed using biofilm assays compared to wild-type *S. aureus*.

METHODS

A combination of biofilm and quantitative real-time-polymerase chain reaction assays were used. In addition, bioinformatic software tools were also utilized.

RESULTS

Significantly more biofilm was created in the *brpR* and *brpS* mutants *vs* wild-type cells. Quantitative real-time polymerase chain reactions showed the *brpS* mutant had differences in transcription of biofilm associated genes that were eight-fold higher for *srtA*, two-fold lower for *lrgA*, and 1.6-fold higher for *cidA* compared to wild-type. Bioinformatic analysis demonstrated that the *S. aureus* BrpR/BrpS TCS had homology to streptococcal late-stage competence proteins involved in cell-death, increased biofilm production, and the development of persister cells.

CONCLUSION

Our study suggests that BrpR/BrpS is a TCS that may repress *S. aureus* biofilm production and be linked to late-stage competence in *S. aureus*.

**Key Words:** Biofilm; Two-component system; Stilbene; *Staphylococcus aureus*; Late-stage competence; SK-03-92

Zank A, Schulte L, Brandon X, Carstensen L, Wescott A, Schwan WR. Mutations of the *brpR* and *brpS* genes affect biofilm formation in *Staphylococcus aureus*. *World J Clin Infect Dis* 2022; In press

**Core Tip:** *Staphylococcus aureus* (*S. aureus*) is a primary cause of skin/soft tissue infections. In this study, we have shown that two previously uncharacterized genes, *brpR* and *brpS*, encode proteins that we believe comprise a two-component system that regulates biofilm formation in *S. aureus*.

**INTRODUCTION**

*Staphylococcus aureus* (*S. aureus*) is a significant pathogen of humans, causing more than 700000 skin/soft tissue infections, nearly 120000 bloodstream infections, and close to 20000 deaths *per* year in the United States[1-3]. Because drug resistance within this species continues to increase, new drugs are needed to treat human infections. Our research group has developed a new stilbene drug labeled SK-03-92 with efficacy against all Gram-positive bacteria that were tested, including methicillin-resistant *S. aureus*[4]. An mRNA microarray was performed on SK-03-92 treated *vs* untreated *S. aureus* cells to try to elucidate the mechanism of action of the drug[5]. From this microarray, the genes for a putative two-component system (TCS) (annotated as *MW2284/MW2285*) were the most downregulated at the transcriptional level. Moreover, transcription of the *srtA* gene (encoding sortase A) was upregulated and the *lrgA* gene encoding an anti-holin was downregulated following SK-03-92 treatment. Additionally, SK-03-92 treatment led to a high degree of persister cells and greater biofilm formation. Because of the effect on biofilm formation, the *MW22284* gene was labeled *brpR* (biofilm regulating protein regulator) and the *MW2285* gene was labeled *brpS* (biofilm regulating protein sensor).

Transcriptional changes of the *srtA* and *lrgA* genes as well as high numbers of persister cells suggested that SK-03-92 treatment may induce late-stage competence in *S.* *aureus*. Although competence allows DNA uptake to occur in heavily stressed cells, transformation is only one effect of bacterial competence. During early competence, which occurs prior to transformation, a large proportion of the stressed bacterial population die *via* holin-induced autolysis[6]. It is this phenomenon that supplies environmental DNA (eDNA) to the remaining cells for DNA uptake. Additionally, the surplus eDNA provides scaffolding for the rapid formation of a biofilm[7]. The final stage of natural competence is metabolic dormancy[8]. Current estimates show that only the youngest 1% of the original population survive to become a dormant cell. Thus, when faced with resource competition, a thriving bacterial colony has the ability to rapidly transform itself into a small group of latent (*i.e.* persister) cells living within a biofilm. These surviving cells re-emerge once environmental resources again become plentiful. This is one strategy used by bacterial cells to survive antibiotic challenge and re-infect the host[9].

The initiation of competence has been shown to rely on a symphony of genetic switches that begin to harmonize when short-sequence amino acids, known as competence stimulating pheromones (CSPs) bind to certain specific membrane proteins. The initiation of the CSP alarmone response has been well characterized in streptococcal species[10]. These membrane proteins are autoinducers that comprise one half of a specific TCS[11]. In *Streptococcus pneumoniae* (*S. pneumoniae*) and *Streptococcus mutans* (*S. mutans*), this response is initiated following the interaction with self-produced auto‑inducing pheromones known as CSPs, which are short, 14 residue peptides. The CSP is then received by the membrane bound sensor kinase ComD (*S. pneumoniae*)[12] or BrsM (*S. mutans*)[13]. Next, ComD or BrsM phosphorylate the cytoplasmic response regulator ComE (*S. pneumoniae*)[12] or BrsR (*S. mutans*)[13],which ultimately controls programmed cell death and persistence. In *S. aureus*, neither the CSP nor the TCS by which CSPs are received have yet been identified.

In this study, we have shown that mutations of the *brpR* and *brpS* genes in *S. aureus* strain Newman showed greater biofilm formation and transcriptional changes of the *srtA* and *lrgA* genes than wild-type *S. aureus*. Furthermore, we have used bioinformatic tools to show that the BrpR/BrpS TCS has homology to the BrsR/BrsM[13] and ComE/ComD[12] late-stage competence TCSs in *S. mutans* and *S. pneumoniae*, respectively. These findings suggest that the BrpR/BrpS TCS may be specific for the reception and resultant signal cascade of a molecule that induces late-stage competence in *S. aureus*.

**MATERIALS AND METHODS**

***Bacterial strains, plasmids, and growth conditions***

All of the bacterial strains and plasmids used in this study are shown in Table 1. The *S. aureus* parent strain Newman was isolated from a human infection[14]. The JE2 strain, created by the University of Nebraska Medical Center, is the *S. aureus* parent strain USA300 LAC CA-MRSA cured of its plasmids[15]. Strains NE272 (*brpS mutant*), NE671 (*brpR mutant*), and NE1787 (*srtA mutant*) are erythromycin-resistant (EmR) mutants representing part of the Nebraska Transposon Mutant Library created by the University of Nebraska Medical Center by *mariner* transposon mutagenesis[15] and obtained from the Network on Antimicrobial Resistance in *S. aureus* (NARSA) strain repository (Table 1). The *E. coli* strain DH5α is a cloning strain with mutations that enable high-efficiency transformation[16]. *S. aureus* strain RN4220 is a transformation efficient strain of *S. aureus*[17].

To clone the *brpR* and *brpS* genes for complementation studies, plasmid pALC2073 was used. This plasmid carries ampicillin and chloramphenicol resistance genes, *E. coli* and Gram-positive origins of replication, and a *xyl/tetO* tetracycline inducible promoter[18].

All media was purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Pittsburgh, PA, United States). All antibiotics were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, United States). *E. coli* strains were grown in Luria (LB) broth shaken at 250 rpm at 37 °C or on Luria agar (LA) incubated at 37 °C. The *E. coli* strains carrying the pALC2073 plasmid were selected for in media containing 100 μg/mL ampicillin.

All *S. aureus* strains were grown in brain heart infusion (BHI) broth with 1% (wt/vol) glucose (BHI-G) or trypticase soy broth shaken at 250 rpm at 37 °C. Agar grown *S. aureus* cultures were passaged on BHI agar at 37 °C. The *mariner* transposon mutant strains were grown in media with 5 μg/mL of erythromycin (Em5). *S. aureus* strains carrying the pALC2073, pXB3-1, or pAMZ1-3 plasmid were selected for in media containing 10 μg/mL of chloramphenicol (Cm10). To induce the *xyl*/*tetO* promoter on the pXB3-1 and pAMZ1-3 plasmids, tetracycline at 0.25 μg/mL was added to the growth medium.

***Transduction of S. aureus***

The *brpR::mariner*, *brpS::mariner*, and *srtA*::*mariner* mutations were transduced into strain Newman using the a 80a bacteriophage[19]. The transductants were then selected for on BHI agar containing Em5. All mutations were verified by polymerase chain reaction (PCR) and biofilm assays.

***Construction of brpS and brpR complementing plasmids***

The *brpR* complementing plasmid was constructed using the pALC2073 backbone[18]. Isolation of pALC2073 plasmid DNA followed the manufacturer’s instructions for the Qiagen QiaPrep plasmid isolation kit (Qiagen, Germantown, MD, United States). The full-length coding region of the *S. aureus* strain MW2 *brpR* gene was PCR amplified using the MW2284I/MW2284M primers (Integrated DNA Technologies, Coralville, IA, United States; Table 2) and the following PCR conditions: 35 cycles, 94 °C 1 min, 57 °C 1 min, 72 °C 1 min. *S. aureus* strain MW2 chromosomal DNA served as a template. The *brpR* DNA was amplified to have a *Kpn*I site on the 5’ end and an *EcoR*Isite on the 3’ end. PCR amplified *brpR* gene product was digested with *Kpn*I and *EcoR*I (New England Biolabs, Ipswich, MA, United States), and then ligated with *Kpn*I/*EcoR*I cut pALC2073 plasmid DNA using T4 DNA ligase (New England Biolabs). Ligated DNA was transformed into *E. coli* strain DH5α cells[16]. Transformants were selected on LA containing 100 μg/mL ampicillin, and one resulting plasmid, plasmid pXB3-1, was used for further experiments.

A recombinant *brpS* complementing plasmid was also constructed. Isolation of pALC2073 plasmid DNA used the same plasmid isolation kit described above. The full-length coding region of the *S. aureus* strain MW2 *brpS* gene was PCR amplified using the GEX-5XB/GEX-5XC primers (Table 2) and the following PCR conditions: 35 cycles, 94 °C 1 min, 57 °C 1 min, 72 °C 1 min. *S. aureus* strain MW2 chromosomal DNA was used as the template. The *brpS* DNA was amplified to have a *Kpn*I site on the 5’ end and an *EcoR*I site on the 3’ end. PCR amplified *brpS* gene product was digested with *Kpn*I and *EcoR*I (New England Biolabs), and then ligated with *Kpn*I/*EcoR*I cut pALC2073 plasmid DNA using T4 DNA ligase (New England Biolabs) immediately downstream from the tetracycline-inducible *xyl/tetO* promoter on pALC2073. Ligated DNA was transformed into *E. coli* strain DH5α cells[16]. Transformants were selected on LA containing 100 mg/mL ampicillin, and one resulting plasmid, plasmid pAMZ1-3, was used for further experiments.

Plasmid DNA from *E. coli* was purified with a Qiagen Plasmid Miniprep Kit (Qiagen) and electroporated into the *S. aureus* strain RN4220[20] using a GenePulser, (Bio-Rad, Hercules, CA, United States) under the following conditions: 100 W capacitance, 25 mF resistance, 2.5 kV charge voltage, 4 s. Transformants were selected for on BHI agar containing Cm10 after one hour of expression in BHI broth. Finally, plasmid DNA was re-isolated from one *S. aureus* strain RN4200 transformant carrying either the pXB3-1 or pAMZ1-3 plasmid using the method noted above with one alteration. The *S. aureus* cells were incubated with 50 μL of lysostaphin (10 mg/mL; Remel, San Diego, CA, United States) for 60 min at 37 °C prior to the first step to facilitate lysis of the staphylococcal cells. Each isolated plasmid DNA sample was then cut with the *Kpn*I and *EcoR*Irestriction endonucleases to verify the insertion. The *S. aureus* strainNewman was then transformed with 10 mL of pXB3-1 or pAMZ1-3 plasmid DNA using electroporation as outlined above and transformants selected for on BHI agar containing Cm10.

***Biofilm assays***

To determine the effect of the *brpR* and *brpS* mutations on the ability of *S. aureus* Newman to form a biofilm, biofilm assays were performed[21]. Briefly, cultures of the *S. aureus* were grown at 37 °C with shaking (250 rpm) overnight in BHI‑G broth with the appropriate antibiotic(s). Each strain was then diluted 1:100 in BHI-G and 220 μL of the solution was placed in microtiter wells in triplicate in a 96-well microtiter plate. The microtiter plates were statically incubated for 24 h at 37 °C to allow a biofilm to form. Each well was then rinsed three times with sterile water. The biofilms were then allowed to settle (10 min), stained with crystal violet dye (0.1% wt/vol) for 10 min, and then washed with sterile water. After allowing the well contents to dry fully in a sterile hood, the dried contents were incubated in 33% acetic acid at room temperature for 30 min. The contents of the well were vigorously curettaged. The optical densities were measured on a SpectraMax M3 96-well microtiter plate reader (Molecular Devices, San Jose, CA, United States) at an optical density of 570 nm. In addition to wild-type Newman cells, Newman *brpR* and Newman *brpS* mutant strains as well as *brpR* and *brpS* mutants containing the pXB3-1 or pAMZ1-3 plasmidswere tested and compared with a Newman *srtA* transposon mutant strain that served as a negative control. To achieve statistical significance, the biofilm assays were performed a minimum of five times in triplicate for each strain.

***Quantitative real-time PCR***

Total RNA was isolated from *S. aureus* strains grown to early logarithmic phase in BHI broth with shaking (250 rpm) incubated at 37 °C using a High Pure RNA Isolation kit (Roche Diagnostics, Indianapolis, IN, United States) with an additional lysostaphin treatment step to help lyse the *S. aureus* cell walls and a DNase I digestion to digest contaminating DNA. To confirm RNA concentration and ensure the integrity of each RNA sample, an aliquot of each RNA sample was analyzed on a Nanodrop machine (Thermo Scientific, Waltham, MA, United States) and electrophoresed through 0.8% agarose gels. The cDNA for each strain was then synthesized from 2 μg of total RNA according to manufacturer’s instruction using a First-Strand Synthesis kit (Life Technologies, Carlsbad, CA, United States). All quantitative real-time PCR (qRT-PCR) trials were performed according to manufacturer’s instruction using the iTaq Universal SYBR Supermix kit (BioRad, Hercules, CA, United States). Oligonucleotide primers that targeted the *ftsZ*, *srtA*, *lrgA*, and *cidA* genes were synthesized (Table 2) by Integrated DNA Technologies. To perform qRT-PCR, the minimum information for publication of quantitative real-time PCR experiments guidelines were followed and the *ftsZ* housekeeping gene was used as a standardization control[22]. All replicates were performed at least three times on a CFX96 qPCR instrument (BioRad, Hercules, CA, United States) under the following conditions: 94 °C, 20 s; 55 °C, 30 s; and 72 °C, 1 min for 35 cycles. The level of target gene transcript from each strain was estimated against the *ftsZ* gene standard curve. Additionally, crossover points for all genes were standardized to the crossover points for *ftsZ* in each sample using the 2-CT formula[23].

***Bioinformatic tools***

The sequenced genomes of *S. aureus* strains MW2 and Newman used in this study are publicly available on GenBank (NCBI, genome assembly ASM1126v1)[24-26]. The protein annotations for all of the bacterial strains included in this study were found on BioCyc or GenBank[26,27]. BioCyc was also used to search for BrpRS homologs downstream of the *mqo2* gene. The UniProt Consortium was used to obtain amino acid FASTA sequences[28]. Domain motifs were sought using NetPHOS, ExPASy, Prosite, and GenomeNet[28-30]. Protter was used to two-dimensionally visualize brpS and brsM[31]. I-TASSER and PyMOL were used together to three dimensionally visualize BrpR and BrpS[32,33]. I-TASSER and PyMol were also used to visually verify DNA binding in residues predicted by DP-Bind[34]. Finally, protein sequence homology analyses were performed by BLASTp (NCBI) with the following parameters: Max target sequences = 100, automatically adjusted parameters for short input sequences, expect threshold = 10, word size = 3, max matches in a query range = 0, matrix = BLOSUM62, gap costs = 11 existence and 1 extension, and a conditional compositional score matrix adjustment[35].

***Statistical analysis***

Calculation of the means, standard deviations, and paired Student’s t-tests were performed using Microsoft Excel. *P* < 0.05 were considered significant.

**RESULTS**

***Alignment of the brpS/brpR genes***

An alignment of the *brpR* and *brpS* genes that encode the BrpR and BrpS proteins is seen on the *S. aureus* MW2 genome sequence (Figure 1)[24]. These genes overlap in a unidirectional in-tandem sequence. The overlapping *brpRS* genes lie just 66 base pairs upstream from the *mqo2* gene, encoding one of the two malate: Quinone oxidoreductases (MQO2) produced by *S. aureus*. The bi-functional MQO2 protein is able to generate oxaloacetate through an oxidation of malate as well as donate electrons to the electron transport chain[36].

***Mutations in the brpR and brpS genes cause greater biofilm formation in S. aureus***

To confirm biofilm formation was linked to BrpR and BrpS, individual *brpR* and *brpS* mutations were moved to the *S. aureus* strain JE2 background[15] to the *S. aureus* strain Newman *via* transduction. Biofilm production of both mutants was compared to the unmutated wild-type *S. aureus* Newman strain. Significantly more biofilm material was produced by the *brpS* and *brpR* mutants (1.8-fold and 1.73-fold higher, respectively, *P* < 0.001) compared to wild-type. Complementation of the *brpR* and *brpS* mutants caused biofilm expression to either return to wild-type levels or there was less biofilm material formed (Figure 2). The *srtA* mutant displayed a 1.73-fold decline in the biofilm forming ability compared to the wild-type strain (*P* < 0.001). This suggested that the putative BrpRS TCS may repress *S. aureus* biofilm production.

***Transcription of srtA and lrgA are regulated by a brpS mutation***

Previously, we showed *srtA* transcription was elevated and *lrgA* transcription was lower after SK-03-92 treatment of *S. aureus* cells compared to untreated cells[5]. The *srtA* gene encodes sortase A[37] and the *lrgA* gene encodes an anti-holin[38] that are important for the formation of biofilms[39,40]. Total RNA was collected during the mid-exponential growth phase from the *S. aureus* Newman *brpS* mutant, *S. aureus* Newman *brpS* mutant containing the pAMZ1-3 plasmid, and wild-type S*. aureus* Newman cells Each RNA sample was converted to cDNA for qRT-PCRs analysis. The *brpS* mutant displayed 8.5-fold higher *srtA* transcription (*P* < 0.008), 2-fold lower *lrgA* transcription (*P* < 0.016), and 1.6-fold higher *cidA* transcription (*P* < 0.43) *vs* the wild-type strain (Figure 3). Complementation of the *brpS* mutation caused *srtA* transcription to drop to a 2.2-fold increase, a 1.3-fold increase in *lrgA* transcription, and a 1.2-fold increase in *cidA* transcription. These results demonstrated that transcription of some biofilm-associated genes was regulated by a mutation in the *brpS* gene.

***BrpR/BrpS homology to other TCS proteins***

BrpR and BrpS homologs were identified by BLAST analyses in multiple Gram-positive bacterial pathogens, including *Bacillus cereus, Clostridioides difficile, Enterococcus faecalis, Lactobacillus species, Staphylococcus haemolyticus, Streptococcus pneumoniae* ComD/ComE*, and S. mutans* BrsR/BrsMas well as three other bacterial species(*Escherichia coli* YehT/YehU*, Mycobacterium tuberculosis* YehT/YehU, and *Chlamydia trachomatis*)[26,35]. Of these, the *S. mutans* BrsR/BrsM TCS that senses CSP and then induces late-stage competence showed the highest homology (Figure 4)[12] .

***Putative structures of the BrpS protein***

*S. aureus* BrpS and *S. mutans* BrsM have a similar arrangement of reactive residues. Lysine, serine, threonine, histidine, tyrosine, and glutamic acid residues were illuminated on a 2-dimensional Protter-generated image of each protein (Figure 5)[29]. This mapping suggested that BrpS and BrsM are partitioned into distinct functional domains separated by the membrane. Functionality appears to occur at the intercellular loop (staphylococcal N’-76-KYTDWSITKAT-86-C’), at the extracellular loop (staphylococcal N’-108-PLTVHY-113-C’), and within a single reactive residue near the membrane at K135 (staphylococcal) within the C’-terminal tail region.

Additionally, the region at the N’-terminus of brpS displays sequence homology with the secreted *S. mutans* and *S. pneumoniae* CSPs (Figure 6). The segment of brpS spanning the regions from N’-1-MKNLKNSLFISLIIGLSLSLFFSMLFADGKYYPLNPQSTIGILYYTHFT-50-C’ showed 56% similarity with CSP (*S. mutans*, 1-SGSLSTFFRLFNRSFTQ A-18)and 30% similarity to CSP-2 (*S. pneumoniae,* 1-EMRISRIILDFLFLRKK-17).

**DISCUSSION**

*S. aureus* causes 65% of biofilm-associated infections *per* year[40,41]. Biofilms provide a defense against host immune defenses as well as most antibiotics. An understanding of what regulates *S. aureus* biofilm formation could lead to treatment options that target this process in *S. aureus*.

Both sortase A (SrtA) and antiholin (LrgA) are important *S. aureus* proteins needed for creation and maintenance of biofilms. Sortase A promotes the covalent anchoring of surface proteins to the cell wall of *S. aureus*[42] that are important in the first stage of biofilm formation. Cell death releases eDNA that is tied to holin/antiholin action. An integral part of mature *S. aureus* biofilms is eDNA[7]. The function of the antiholin LrgA is to prevent cell autolysis by complexing with CidA holins[38,43].

In this study, we have shown that mutations in either the *brpR* or *brpS* gene cause an increase in biofilm formation as well as transcriptional changes of the *srtA* and *lrgA* genes, which are linked events. Previous studies with transposon mutants of what was an uncharacterized gene, that we have named *brpS,* displayed better biofilm formation than the wild-type strain[44,45]. Strains with a mutated *lrgA* gene have also been shown to produce increased levels of biofilms[46]. Another study has shown that cell lysis caused eDNA to be rapidly produced that could act as a scaffolding for newly forming biofilms[10].

The *in silico* data; biofilm results with the *brpR* and *brpS* mutants; and the data from the transcript abundance changes of the *lrgA, srtA, brpR,* and *brpS* genes suggest that BrpR/BrpS comprise a TCS that may be involved in late-stage competence. From the *in silico* analysis, we speculate that the BrpR protein (that possesses an apparent LytTR DNA binding-motif[47]) may repress *srtA* transcription. Other proteins that have LytTR motifs, such as BrsR and ComE, have been shown to have multifunctional activities tied to activation and repression[47-49]. Further analysis is required to show that BrpR is capable of binding to this region.

From the data presented, we speculate that BrpS is a receptor for a CSP-like pheromone secreted by *S. aureus* as a response to competition for resources. The leader peptide of BrpS may function to competitively antagonize the extracellular receptor portion of BrpS from the CSPs of competitive species, such as *S. mutans* and *S. pneumoniae,* that inhabit the human upper respiratory tract.

A number of previously completed studies focused on biofilm production and bacterial cell viability due to interactions with CSP-like pheromones. A study by Zhang *et al*[49] demonstrated that within *S. mutans* there was a 76.3% decline in cell viability and biofilm mass increased by 89.3% following the addition of CSP to bacterial growth media[49]. In addition, supernatant collected from *S. mutans* that wasco-cultured with *Aggregatibacter actinomycetemcomitans* caused a 1.3-fold rise in biofilm production within *S. mutans*[50]. Ample evidence of cell death after CSP exposure has been documented by several studies, however, biofilm production has not been normalized to the viable bacterial cells that remain[51-53]. Nevertheless, a number of Gram-positive bacterial species show cell viability and subsequent biofilm production correlate with the level of CSP added to the media. Further studies should be done to assess the actual increase in biofilm formation by taking into account the findings that competence is accompanied by massive cellular death.

We also believe that there may be a connection between metabolic dormancy and the BrpR/BrpS TCS. If malate production is interrupted after BrpR binds to the sigma factor binding sites, malate conversion to oxalacetate would be halted. As a consequence of this interruption, any acetyl groups generated by acetyl-CoA would not interact with citrate within the citric-acid cycle. Thus, too much acetyl-CoA would arise within the cell. Because these functional groups would be liberated, it is possible that there would be an epigenetic modification and BrpR would be rapidly released from the *srtA* gene enhancer region. By freeing BrpR from the *srtA* gene enhancer region, additional BrpR molecules would be available to interact with sigma factors, blocking transcription of *brpRS* that would lead to even less transcription of the *mqo2* gene.The work by Zhang *et al*[54]used profiling of lysine acetylomes in *S. aureus* and *E. coli* to identify asequence motif, whichsupportsour idea that BrpR may epigenetically block DNA-binding[54]. As part of that study, 412 proteins and 1361 lysine sites were cross-referenced against each other, which led to a conserved motif, N’-RLYELExQLxxxFIRISKxxEIVN-C’, being identified. BrpR has this conserved motif, which is very well conserved among a number of bacterial species. By shutting down malate expression, persister cells could form suddenly as a response to late-stage competence or treatment with the SK-03-92 drug. Thus, BrpR repression of malate production could be connected to formation of persister cells that is a feature of late-stage competence.

**CONCLUSION**

Our study suggests that BrpR/BrpS is a TCS that may repress *S. aureus* biofilm production and be linked to late-stage competence in *S. aureus*.

**ARTICLE HIGHLIGHTS**

***Research background***

*Staphylococcus aureus* (*S. aureus*) is a primary cause of skin/soft tissue infections. Biofilm formation is a key component of *S. aureus* pathogenesis. Thus, an understanding of what regulates biofilm formation in *S. aureus* is important.

***Research motivation***

We were interested in characterizing two open reading frames that we thought were tied to biofilm formation in *S. aureus*.

***Research objectives***

Determine if mutations in the *brpR* and *brpS* genes affected biofilm formation and what the respective proteins had homologies with.

***Research methods***

We used biofilm assays and quantitative real-time-polymerase chain reaction (qRT-PCR) analysis to test *brpR* and *brpS* mutants compared to the parent strain of *S. aureus*. Bioinformatic tools were used to determine what roles the BrpR and BrpS proteins may play in *S. aureus* cells.

***Research results***

The biofilm and qRT-PCR analyses demonstrated that mutations in the *brpR* and *brpS* genes affected biofilm formation in *S. aureus* and led to transcriptional differences in key biofilm-related genes as compared to the parent strain. Further, the BrpR and BrpS proteins share homologies with proteins involved in late-stage competence in streptococcal species.

***Research conclusions***

BrpR/BrpS are likely a new two-component system which regulates biofilm formation in *S. aureus*.

***Research perspectives***

A better understanding of a new regulator of *S. aureus* biofilm formation has been identified.

**ACKNOWLEDGEMENTS**

We wish to thank Jean Lee, Ambrose Cheung, Jo Handelsman, and NARSA for bacterial strains and plasmids used in this study as well as Jennifer Klein and the Molecular Biology Laboratory students who ran some of the qRT-PCRs.

**REFERENCES**

1 **Suaya JA**, Mera RM, Cassidy A, O'Hara P, Amrine-Madsen H, Burstin S, Miller LG. Incidence and cost of hospitalizations associated with *Staphylococcus aureus* skin and soft tissue infections in the United States from 2001 through 2009. *BMC Infect Dis* 2014; **14**: 296 [PMID: 24889406 DOI: 10.1186/1471-2334-14-296]

2 **Klein EY**, Sun L, Smith DL, Laxminarayan R. The changing epidemiology of methicillin-resistant *Staphylococcus aureus* in the United States: a national observational study. *Am J Epidemiol* 2013; **177**: 666-674 [PMID: 23449778 DOI: 10.1093/aje/kws273]

3 **Klein EY**, Mojica N, Jiang W, Cosgrove SE, Septimus E, Morgan DJ, Laxminarayan R. Trends in methicillin-resistant *Staphylococcus aureus* hospitalizations in the United States, 2010-2014. *Clin Infect Dis* 2017; **65**: 1921-1923 [PMID: 29020322 DOI: 10.1093/cid/cix640]

4 **Schwan WR**, Kabir MS, Kallaus M, Krueger S, Monte A, Cook JM. Synthesis and minimum inhibitory concentrations of SK-03-92 against *Staphylococcus aureus* and other gram-positive bacteria. *J Infect Chemother* 2012; **18**: 124-126 [PMID: 21739106 DOI: 10.1007/s10156-011-0273-7]

5 **Schwan WR**, Polanowski R, Dunman PM, Medina-Bielski S, Lane M, Rott M, Lipker L, Wescott A, Monte A, Cook JM, Baumann DD, Tiruveedhula VVNPB, Witzigmann CM, Mikel C, Rahman MT. Identification of *Staphylococcus aureus* cellular pathways affected by the stilbenoid lead drug SK-03-92 using a microarray. *Antibiotics (Basel)* 2017; **6** [PMID: 28892020 DOI: 10.3390/antibiotics6030017]

6 **Rice KC**, Bayles KW. Molecular control of bacterial death and lysis. *Microbiol Mol Biol Rev* 2008; **72**: 85-109, table of contents [PMID: 18322035 DOI: 10.1128/MMBR.00030-07]

7 **Okshevsky M**, Meyer RL. The role of extracellular DNA in the establishment, maintenance and perpetuation of bacterial biofilms. *Crit Rev Microbiol* 2015; **41**: 341-352 [PMID: 24303798 DOI: 10.3109/1040841X.2013.841639]

8 **Wood TK**, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. *Appl Environ Microbiol* 2013; **79**: 7116-7121 [PMID: 24038684 DOI: 10.1128/AEM.02636-13]

9 **Zhang Y**. Persisters, persistent infections and the Yin-Yang model. *Emerg Microbes Infect* 2014; **3**: e3 [PMID: 26038493 DOI: 10.1038/emi.2014.3]

10 **Dufour D**, Lévesque CM. Bacterial behaviors associated with the quorum-sensing peptide pheromone ('alarmone') in streptococci. *Future Microbiol* 2013; **8**: 593-605 [PMID: 23642115 DOI: 10.2217/fmb.13.23]

11 **Cozzone AJ**. ATP-dependent protein kinases in bacteria. *J Cell Biochem* 1993; **51**: 7-13 [PMID: 8432746 DOI: 10.1002/jcb.240510103]

12 **Pestova EV**, Håvarstein LS, Morrison DA. Regulation of competence for genetic transformation in *Streptococcus pneumoniae* by an auto-induced peptide pheromone and a two-component regulatory system. *Mol Microbiol* 1996; **21**: 853-862 [PMID: 8878046 DOI: 10.1046/j.1365-2958.1996.501417.x]

13 **Xie Z**, Okinaga T, Niu G, Qi F, Merritt J. Identification of a novel bacteriocin regulatory system in *Streptococcus mutans*. *Mol Microbiol* 2010; **78**: 1431-1447 [PMID: 21143316 DOI: 10.1111/j.1365-2958.2010.07417.x]

14 **Duthie ES**, Lorenz LL. Staphylococcal coagulase; mode of action and antigenicity. *J Gen Microbiol* 1952; **6**: 95-107 [PMID: 14927856 DOI: 10.1099/00221287-6-1-2-95]

15 **Fey PD**, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles KW. A genetic resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus aureus* genes. *mBio* 2013; **4**: e00537-e00512 [PMID: 23404398 DOI: 10.1128/mBio.00537-12]

16 **Hanahan D**. Studies on transformation of *Escherichia coli* with plasmids. *J Mol Biol* 1983; **166**: 557-580 [PMID: 6345791 DOI: 10.1016/s0022-2836(83)80284-8]

17 **Novick RP.** The *Staphylococcus* as a molecular genetic system. “Molecular Biology of the Staphylococci, ” R. P. Novick ed, pp. 1–40, VCH Publishers: New York, NY, USA, 1990.

18 **Bateman BT**, Donegan NP, Jarry TM, Palma M, Cheung AL. Evaluation of a tetracycline-inducible promoter in *Staphylococcus aureus* in vitro and in vivo and its application in demonstrating the role of sigB in microcolony formation. *Infect Immun* 2001; **69**: 7851-7857 [PMID: 11705967 DOI: 10.1128/IAI.69.12.7851-7857.2001]

19 **Kloss WE**, Pattee PA. Transduction analysis of the histidine region in *Staphylococcus aureus*. *J Gen Microbiol* 1965; **39**: 195-207 [PMID: 14324965 DOI: 10.1099/00221287-39-2-195]

20 **Iandolo JJ,** Kraemer GR. High frequency transformation of *Staphylococcus aureus* by electroporation. *Curr Microbiol* 1990; **21:** 373–376 [DOI: 10.1007/BF02199440]

21 **Stepanović S**, Vuković D, Jezek P, Pavlović M, Svabic-Vlahović M. Influence of dynamic conditions on biofilm formation by staphylococci. *Eur J Clin Microbiol Infect Dis* 2001; **20**: 502-504 [PMID: 11561809 DOI: 10.1007/s100960100534]

22 **Bustin SA**, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem* 2009; **55**: 611-622 [PMID: 19246619 DOI: 10.1373/clinchem.2008.112797]

23 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

24 **Baba T**, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K. Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet* 2002; **359**: 1819-1827 [PMID: 12044378 DOI: 10.1016/s0140-6736(02)08713-5]

25 **Baba T**, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. Genome sequence of *Staphylococcus aureus* strain Newman and comparative analysis of staphylococcal genomes: polymorphism and evolution of two major pathogenicity islands. *J Bacteriol* 2008; **190**: 300-310 [PMID: 17951380 DOI: 10.1128/JB.01000-07]

26 **Clark K**, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. GenBank. *Nucleic Acids Res* 2016; **44**: D67-D72 [PMID: 26590407 DOI: 10.1093/nar/gkv1276]

27 **Karp PD**, Billington R, Caspi R, Fulcher CA, Latendresse M, Kothari A, Keseler IM, Krummenacker M, Midford PE, Ong Q, Ong WK, Paley SM, Subhraveti P. The BioCyc collection of microbial genomes and metabolic pathways. *Brief Bioinform* 2019; **20**: 1085-1093 [PMID: 29447345 DOI: 10.1093/bib/bbx085]

28 **UniProt Consortium T**. UniProt: the universal protein knowledgebase. *Nucleic Acids Res* 2018; **46**: 2699 [PMID: 29425356 DOI: 10.1093/nar/gky092]

29 **Omasits U**, Ahrens CH, Müller S, Wollscheid B. Protter: interactive protein feature visualization and integration with experimental proteomic data. *Bioinformatics* 2014; **30**: 884-886 [PMID: 24162465 DOI: 10.1093/bioinformatics/btt607]

30 **Blom N**, Sicheritz-Pontén T, Gupta R, Gammeltoft S, Brunak S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. *Proteomics* 2004; **4**: 1633-1649 [PMID: 15174133 DOI: 10.1002/pmic.200300771]

31 **de Castro E**, Sigrist CJ, Gattiker A, Bulliard V, Langendijk-Genevaux PS, Gasteiger E, Bairoch A, Hulo N. ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins. *Nucleic Acids Res* 2006; **34**: W362-W365 [PMID: 16845026 DOI: 10.1093/nar/gkl124]

32 **Yang J**, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. *Nat Methods* 2015; **12**: 7-8 [PMID: 25549265 DOI: 10.1038/nmeth.3213]

33 [**Delano**](https://xueshu.baidu.com/s?wd=author%3A%28WL%20Delano%29%20&tn=SE_baiduxueshu_c1gjeupa&ie=utf-8&sc_f_para=sc_hilight%3Dperson) **WL.** The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.

34 **Hwang S**, Gou Z, Kuznetsov IB. DP-Bind: a web server for sequence-based prediction of DNA-binding residues in DNA-binding proteins. *Bioinformatics* 2007; **23**: 634-636 [PMID: 17237068 DOI: 10.1093/bioinformatics/btl672]

35 **Altschul SF**, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990; **215**: 403-410 [PMID: 2231712 DOI: 10.1016/S0022-2836(05)80360-2]

36 **Molenaar D**, van der Rest ME, Petrović S. Biochemical and genetic characterization of the membrane-associated malate dehydrogenase (acceptor) from *Corynebacterium glutamicum*. *Eur J Biochem* 1998; **254**: 395-403 [PMID: 9660197 DOI: 10.1046/j.1432-1327.1998.2540395.x]

37 **Mazmanian SK**, Liu G, Ton-That H, Schneewind O. *Staphylococcus aureus* sortase, an enzyme that anchors surface proteins to the cell wall. *Science* 1999; **285**: 760-763 [PMID: 10427003 DOI: 10.1126/science.285.5428.760]

38 **Ranjit DK**, Endres JL, Bayles KW. *Staphylococcus aureus* CidA and LrgA proteins exhibit holin-like properties. *J Bacteriol* 2011; **193**: 2468-2476 [PMID: 21421752 DOI: 10.1128/JB.01545-10]

39 **Kavanaugh JS**, Flack CE, Lister J, Ricker EB, Ibberson CB, Jenul C, Moormeier DE, Delmain EA, Bayles KW, Horswill AR. Identification of extracellular DNA-binding proteins in the biofilm matrix. *mBio* 2019; **10** [PMID: 31239382 DOI: 10.1128/mBio.01137-19]

40 **Archer NK**, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. *Staphylococcus aureus* biofilms: properties, regulation, and roles in human disease. *Virulence* 2011; **2**: 445-459 [PMID: 21921685 DOI: 10.4161/viru.2.5.17724]

41 **Otto M**. Staphylococcal biofilms. *Curr Top Microbiol Immunol* 2008; **322**: 207-228 [PMID: 18453278 DOI: 10.1007/978-3-540-75418-3\_10]

42 **Marraffini LA**, Dedent AC, Schneewind O. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. *Microbiol Mol Biol Rev* 2006; **70**: 192-221 [PMID: 16524923 DOI: 10.1128/MMBR.70.1.192-221.2006]

43 **Sadykov MR**, Bayles KW. The control of death and lysis in staphylococcal biofilms: a coordination of physiological signals. *Curr Opin Microbiol* 2012; **15**: 211-215 [PMID: 22221897 DOI: 10.1016/j.mib.2011.12.010]

44 **Kadurugamuwa JL**, Sin L, Albert E, Yu J, Francis K, DeBoer M, Rubin M, Bellinger-Kawahara C, Parr TR Jr, Contag PR. Direct continuous method for monitoring biofilm infection in a mouse model. *Infect Immun* 2003; **71**: 882-890 [PMID: 12540570 DOI: 10.1128/IAI.71.2.882-890.2003]

45 **Xiong YQ**, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat *Staphylococcus aureus* endocarditis model. *Antimicrob Agents Chemother* 2005; **49**: 380-387 [PMID: 15616318 DOI: 10.1128/AAC.49.1.380-387.2005]

46 **Brunskill EW**, Bayles KW. Identification of LytSR-regulated genes from *Staphylococcus aureus*. *J Bacteriol* 1996; **178**: 5810-5812 [PMID: 8824633 DOI: 10.1128/jb.178.19.5810-5812.1996]

47 **Okinaga T**, Xie Z, Niu G, Qi F, Merritt J. Examination of the *hdrRM* regulon yields insight into the competence system of *Streptococcus mutans*. *Mol Oral Microbiol* 2010; **25**: 165-177 [PMID: 20536745 DOI: 10.1111/j.2041-1014.2010.00574.x]

48 **Kreth J**, Hung DCI, Merritt J, Perry J, Zhu L, Goodman SD, Cvitkovitch DG, Shi W, Qi F. The response regulator ComE in *Streptococcus mutans* functions both as a transcription activator of mutacin production and repressor of CSP biosynthesis. *Microbiology (Reading)* 2007; **153**: 1799-1807 [PMID: 17526837 DOI: 10.1099/mic.0.2007/005975-0]

49 **Zhang K**, Ou M, Wang W, Ling J. Effects of quorum sensing on cell viability in *Streptococcus mutans* biofilm formation. *Biochem Biophys Res Commun* 2009; **379**: 933-938 [PMID: 19138664 DOI: 10.1016/j.bbrc.2008.12.175]

50 **Szafrański SP**, Deng ZL, Tomasch J, Jarek M, Bhuju S, Rohde M, Sztajer H, Wagner-Döbler I. Quorum sensing of *Streptococcus mutans* is activated by *Aggregatibacter actinomycetemcomitans* and by the periodontal microbiome. *BMC Genomics* 2017; **18**: 238 [PMID: 28320314 DOI: 10.1186/s12864-017-3618-5]

51 **Qi F**, Kreth J, Lévesque CM, Kay O, Mair RW, Shi W, Cvitkovitch DG, Goodman SD. Peptide pheromone induced cell death of *Streptococcus mutans*. *FEMS Microbiol Lett* 2005; **251**: 321-326 [PMID: 16165324 DOI: 10.1016/j.femsle.2005.08.018]

52 **Ween O**, Gaustad P, Håvarstein LS. Identification of DNA binding sites for ComE, a key regulator of natural competence in *Streptococcus pneumoniae*. *Mol Microbiol* 1999; **33**: 817-827 [PMID: 10447890 DOI: 10.1046/j.1365-2958.1999.01528.x]

53 **Perry JA**, Cvitkovitch DG, Lévesque CM. Cell death in *Streptococcus mutans* biofilms: a link between CSP and extracellular DNA. *FEMS Microbiol Lett* 2009; **299**: 261-266 [PMID: 19735463 DOI: 10.1111/j.1574-6968.2009.01758.x]

54 **Zhang Y,** Wu ZX, Wan XL, Liu P, Zhang JB, Ye Y, Zhao YM, Tan MJ. Comprehensive profiling of lysine acetylome in *Staphylococcus aureus*. *Sci China Chem* 2014; **57:** 732-738 [DOI: 10.1007/s11426-014-5100-4]

**Footnotes**

**Institutional review board statement:** No humans or samples from human were used in this study.

**Institutional animal care and use committee statement:** No animals were used in this study.

**Conflict-of-interest statement:** W.R.S. holds a composition of matter and use patent covering the SK-03-92 Lead compound.

**Data sharing statement:** The authors will share their data with whomever asks.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 2, 2021

**First decision:** November 22, 2021

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Barik S, Sun Y **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 Schematic representation of the chromosomal position and organization of the *brpR*, *brpS*, and *mqo2* genes in the *Staphylococcus aureus* strain MW2 genome.**



**Figure 2 Effect of *brpR* and *brpS* mutations and complementation on *Staphylococcus aureus* biofilm formation.** All experiments represent the mean ± SD from five different runs done in triplicate for each strain. Biofilm formation was done on wild-type *Staphylococcus aureus* (*S. aureus*)strain Newman(WT, open column), *S. aureus* Newman *srtA* mutant (black column), *S. aureus* Newman *brpS* mutant (right striped column), *S. aureus* Newman *brpS* mutant*/*pAMZ1-3 (left striped column)*, S. aureus* Newman *brpR* mutant (dark right striped column)*,* and *S. aureus* Newman *brpR* mutant*/*pXB31 (dark left striped column).Differences were statistically compared by analysis of variance where a*P* < 0.001.



**Figure 3 Quantitative reverse transcribed-polymerase chain reaction results of *Staphylococcus aureus* Newman *cidA*, *lrgA*, and *srtA* transcription in wild-type bacteria (standardized to 0) compared to a *Staphylococcus aureus* Newman *brpS* mutant (black column) and the complemented *brpS* mutant (white column).** The data represents the mean ± SD from three separate runs.



**Figure 4 Bioinformatic comparison of the BrsRM proteins of *Streptococcus mutans* with the BrpRS proteins of *Staphylococcus aureus*.** A: BrsM, a two-component system membrane protein responsible for activating competence in response to sensing competitor organisms within a niche, shares sequence similarity with BrpS; B: BrsR, which is the cognate response regulator to BrsM, shares sequence similarity with BrpR. BLASTp NCBI. Algorithm parameters: Max target sequences = 100, automatically adjusted parameters for short input sequences, expect threshold = 10, word size = 3, max matches in a query range = 0, matrix = BLOSUM62, gap costs = 11 existence and 1 extension, and a conditional compositional score matrix adjustment.



**Figure 5 Highlight of amino acid residues shared by competence stimulating pheromone, competence stimulating pheromone-2, and BrpS.** The predicted exterior segment of BrpS, which spans N’-1-MKNLKNSLFISLIIGLSLSLFFSMLFADGKYYPLNPQSTIGILYYTHFT-50-C’, was compared to competence stimulating pheromone (CSP) and CSP-2 by BLASTp. The competence stimulating peptides of *Streptococcus mutans* (1-SGSLSTFFRLFNRSFTQA-18, CSP)and *Streptococcus pneumoniae* (1-EMRISRIILDFLFLRKK-17, CSP-2) has 56% similarity to CSP and 30% similarity to CSP-2. CSP: Competence stimulating pheromone.



**Figure 6 Comparison of the sequences and predicted topologies of the putative two-component system membrane sensor BrpS (left, *Staphylococcus aureus*) and BrsM (right, *Streptococcus mutans*).** According to this prediction, residues likely to be reactive (red) are topologically arranged in similar loci among both proteins. Intra is proposed to correspond with the cytoplasmic space, and extra is proposed to correspond with the extracellular milieu of the cell. Figures generated by Protter.

**Table 1 Bacterial strains and plasmids used in this study**

|  |  |  |
| --- | --- | --- |
| **Bacterial strain** | **Description** | **Ref.** |
| ***E. coli*** |  |  |
| DH5 | Transformation efficient *E. coli* strain  | [16] |
| ***S. aureus*** |  |  |
| Newman | *S. aureus* clinical isolate | [14] |
| JE2 | *S. aureus* USA300 MRSA strain | [15] |
| NE272 | *S. aureus* JE2 *brpS*::*mariner* mutant | [15] |
| NE671 | *S. aureus* JE2 *brpR*::*mariner* mutant | [15] |
| NE1787 | *S. aureus* JE2 *srtA*::*mariner* mutant | [15] |
| RN4220 | Transformation-efficient *S. aureus* strain  | [17] |
| Newman *brpR* | *S. aureus* Newman *brpR*::*mariner* mutant | This study |
| Newman *brpS* | *S. aureus* Newman *brpS*::*mariner* mutant | This study |
| Newman *srtA* | *S. aureus* Newman *srtA*::*mariner* mutant | This study |
| **Plasmids** |  |  |
| pXB3-1 | pALC2073 plasmid with the *brpR* gene inserted | This study |
| pALC2073 | Cloning vector with Apr, Cmr, and Tcr genes, and a Tc-inducible promoter | [18] |
| pAMZ1-3 | pALC2073 plasmid with the *brpS* gene inserted | This study |

**Table 2 Primers used in this study**

|  |  |
| --- | --- |
| **Primer** | **Sequence** |
| GEX-5XC | 5’- CCTAGGAGATCTCTTTCTGTC -3’ |
| GEX-5XB | 5’- GTTAATTTTACTAAACTTAAG -3’ |
| MW2284I | 5’- GAGCAGGTACCATGATGAAACTCAATTTATTTATCAATGCAAAAG-3’ |
| MW2284M | 5’- CAGCGAATTCTCAATGGTGATGGTGATGTATTGATAATCGCTCCTTTATAGATTTTAAAA -3’ |
| CidA1 | 5’- TGCAACGATACATGTTCCTATG -3’ |
| CidA2 | 5’- CTACAACTAGGAATCATCATTGTG -3’ |
| LrgA1 | 5’- GCATCAAAACCAGCACACTTT -3’ |
| LrgA2 | 5’- GACTTCGCCTAACTTAACAGC -3’ |
| SaFtsZ1 | 5’- GGTGTAGGTGGTGGCGGTAA -3’ |
| SaFtsZ2 | 5’- TCATTGGCGTAGATTTGTC -3’ |
| SrtA1 | 5’- TCGCTGGTGTGGTACTTATC -3’ |
| SrtA2 | 5’- CAGGTGTTGCTGGTCCTGGA -3’ |